![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Amgen announced plans to participate in the World Medical Innovation Forum™ on cancer held April 25-27, 2016, in Boston. The World Medical Innovation Forum is a global gathering of senior corporate, investor and academic leaders. The forum was established to respond to the intensifying transformation of healthcare and its impact on innovation. This is the second year Amgen has participated in this event as a sponsor.
Three senior leaders from Amgen are scheduled to speak:
Robert A. Bradway, chairman and chief executive officer, will participate in a fireside chat with Caroline Chen, a biotechnology and healthcare reporter at Bloomberg. The discussion will highlight Amgen’s strategic focus in oncology/hematology, its approach to innovation, and its investment in immuno-oncology and combination therapies. This event is scheduled for 10:25 a.m. ET on Tuesday, April 26.
Sean E. Harper, M.D., executive vice president of Research and Development, will participate on the “Creating a Disruptive Cancer Pipeline” panel moderated by Robert Tepper, M.D., a partner at Third Rock Ventures and an adjunct professor at Harvard Medical School. The expert panel members will discuss the considerations in cancer pipeline development, the tradeoffs and what it takes to maintain success over time. The panel is scheduled for 2:20 p.m. ET on Monday, April 25.
Sean E. Harper, M.D., executive vice president of Research and Development, will participate on the “Creating a Disruptive Cancer Pipeline” panel moderated by Robert Tepper, M.D., a partner at Third Rock Ventures and an adjunct professor at Harvard Medical School. The expert panel members will discuss the considerations in cancer pipeline development, the tradeoffs and what it takes to maintain success over time. The panel is scheduled for 2:20 p.m. ET on Monday, April 25.
